- Home
- HRTX vs NPCE Comparison
HRTX vs NPCE Comparison
Compare HRTX & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRTX
- NPCE
- Stock Information
- Founded
- HRTX 1983
- NPCE 1997
- Country
- HRTX United States
- NPCE United States
- Employees
- HRTX N/A
- NPCE N/A
- Industry
- HRTX Biotechnology: Pharmaceutical Preparations
- NPCE Medical Specialities
- Sector
- HRTX Health Care
- NPCE Health Care
- Exchange
- HRTX Nasdaq
- NPCE Nasdaq
- Market Cap
- HRTX 350.4M
- NPCE 358.3M
- IPO Year
- HRTX 1987
- NPCE 2021
- Fundamental
- Price
- HRTX $2.11
- NPCE $12.89
- Analyst Decision
- HRTX Strong Buy
- NPCE Buy
- Analyst Count
- HRTX 2
- NPCE 6
- Target Price
- HRTX $5.50
- NPCE $14.83
- AVG Volume (30 Days)
- HRTX 1.8M
- NPCE 135.0K
- Earning Date
- HRTX 05-06-2025
- NPCE 05-13-2025
- Dividend Yield
- HRTX N/A
- NPCE N/A
- EPS Growth
- HRTX N/A
- NPCE N/A
- EPS
- HRTX N/A
- NPCE N/A
- Revenue
- HRTX $148,518,000.00
- NPCE $79,906,000.00
- Revenue This Year
- HRTX $11.18
- NPCE $19.53
- Revenue Next Year
- HRTX $13.15
- NPCE $11.83
- P/E Ratio
- HRTX N/A
- NPCE N/A
- Revenue Growth
- HRTX 12.43
- NPCE 22.14
- 52 Week Low
- HRTX $1.04
- NPCE $5.45
- 52 Week High
- HRTX $3.93
- NPCE $15.11
- Technical
- Relative Strength Index (RSI)
- HRTX 47.04
- NPCE 62.74
- Support Level
- HRTX $2.00
- NPCE $11.19
- Resistance Level
- HRTX $2.61
- NPCE $12.49
- Average True Range (ATR)
- HRTX 0.18
- NPCE 0.69
- MACD
- HRTX -0.01
- NPCE 0.19
- Stochastic Oscillator
- HRTX 20.63
- NPCE 89.17
About HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.